| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.5 MB | Adobe PDF |
Authors
Abstract(s)
Introdução: O carcinoma da próstata é a neoplasia mais comum e a terceira causa de morte por cancro no homem. Atualmente, existe uma variedade de opções disponíveis para o tratamento do carcinoma da próstata metastizado e resistente à castração (mCRPC) como é o exemplo da abiraterona e da enzalutamida, focados nesta análise.
Objetivo do estudo: Analisar as caraterísticas, o tratamento e outcomes de pacientes com mCRPC tratados com abiraterona ou enzalutamida e correlacionar com a sobrevida livre de progressão e sobrevida média global. Averiguar a influência das variáveis idade, score de Gleason, duração do tratamento antineoplásico anterior e PSA no início do tratamento na resposta à terapêutica.
Metodologia: Foi realizado um estudo retrospetivo baseado em dados de um período pregresso (desde a introdução destes medicamentos no hospital, 19 de Dezembro de 2013 até dia 31 de Julho de 2017) no Centro Hospitalar Cova da Beira. Foram recolhidas diversas variáveis como idade, ECOG, score de Gleason, existência ou não de metastização, locais de metastização, terapêuticas antineoplásicas anteriores, terapêutica associada, comorbilidades, doentes quimio-naive ou pós-quimioterapia, PSA no início do tratamento e a duração do tratamento.
Resultados: A amostra é constituída por 21 doentes com mCRPC sem quimioterapia prévia. A idade média dos doentes foi de 72,1 anos (52–90 anos). Não se verificou uma diferença estatisticamente significativa (p>0,05), entre a abiraterona e a enzalutamida no que concerne à percentagem de doentes com redução de PSA a 6 meses =50%, nem na sobrevida média global (22,0 meses para a abiraterona vs não alcançado para a enzalutamida). De igual modo, não foi observada uma influência significativa (p>0,05) das seguintes variáveis analisadas: a) idade dos doentes na redução da PSA a 6 meses =50%; b) score de Gleason no valor médio e distribuição de valores da redução PSA (%) a 6 meses; c) tratamento antineoplásico anterior =12 meses no valor médio e distribuição de valores da redução PSA (%) a 6 meses; d) valor do PSA no início do tratamento na percentagem de doentes com redução de PSA a 6 meses =50%.
Conclusões: O tratamento com abiraterona ou com enzalutamida não conduziu a diferenças significativas nos outcomes de doentes com mCRPC sem quimioterapia prévia. Do mesmo modo, nenhuma das variáveis analisadas influenciou significativamente os resultados do tratamento.
Background: Prostate cancer is the most common malignancy and the third leading cause of cancer death in man. Currently, there are a variety of options available for the treatment of metastatic castration-resistant prostate cancer (mCRPC), as is the case with abiraterone and enzalutamide, focused on this analysis. Purpose: Analyze the characteristics, treatment and outcomes of patients receiving mCRPC treated with abiraterone or enzalutamide and correlate with progression-free survival and overall mean survival. Check the influence of the variables age, Gleason score, duration of previous antineoplastic treatment and PSA at the beginning of treatment in response to treatment. Methodology: A retrospective study based on data from a previous period (from the introduction of these drugs in the hospital until July 31, 2017) was performed at our hospital. Several variables such as age, ECOG, Gleason score, metastatic existence or not, metastatic sites, previous antineoplastic therapies, associated therapeutics, comorbidities, chemo-naive or post-chemotherapy patients, PSA at the beginning of treatment and the duration of treatment. Results: The sample consisted of 21 mCRPC patients without prior chemotherapy. The mean age of the patients was 72.1 years (52-90 years). There was no statistically significant difference (p> 0.05) between abiraterone and enzalutamide in the percentage of patients with a 6 month PSA reduction =50%, or overall mean survival (22.0 months for abiraterone vs not obtained for enzalutamide). Likewise, a significant influence (p> 0.05) of the following analyzed variables was not observed: a) patients' age at 6 month PSA reduction =50%; b) Gleason score in the mean value and distribution of PSA reduction (%) at 6 months; c) previous antineoplastic treatment =12 months in the mean value and distribution of PSA reduction values (%) at 6 months; d) PSA value at baseline in the proportion of patients with 6 month PSA reduction =50%. Conclusions: Treatment with abiraterone or with enzalutamide did not lead to significant differences in the outcomes of patients with mCRPC without prior chemotherapy. Likewise, none of the analyzed variables significantly influenced treatment outcomes.
Background: Prostate cancer is the most common malignancy and the third leading cause of cancer death in man. Currently, there are a variety of options available for the treatment of metastatic castration-resistant prostate cancer (mCRPC), as is the case with abiraterone and enzalutamide, focused on this analysis. Purpose: Analyze the characteristics, treatment and outcomes of patients receiving mCRPC treated with abiraterone or enzalutamide and correlate with progression-free survival and overall mean survival. Check the influence of the variables age, Gleason score, duration of previous antineoplastic treatment and PSA at the beginning of treatment in response to treatment. Methodology: A retrospective study based on data from a previous period (from the introduction of these drugs in the hospital until July 31, 2017) was performed at our hospital. Several variables such as age, ECOG, Gleason score, metastatic existence or not, metastatic sites, previous antineoplastic therapies, associated therapeutics, comorbidities, chemo-naive or post-chemotherapy patients, PSA at the beginning of treatment and the duration of treatment. Results: The sample consisted of 21 mCRPC patients without prior chemotherapy. The mean age of the patients was 72.1 years (52-90 years). There was no statistically significant difference (p> 0.05) between abiraterone and enzalutamide in the percentage of patients with a 6 month PSA reduction =50%, or overall mean survival (22.0 months for abiraterone vs not obtained for enzalutamide). Likewise, a significant influence (p> 0.05) of the following analyzed variables was not observed: a) patients' age at 6 month PSA reduction =50%; b) Gleason score in the mean value and distribution of PSA reduction (%) at 6 months; c) previous antineoplastic treatment =12 months in the mean value and distribution of PSA reduction values (%) at 6 months; d) PSA value at baseline in the proportion of patients with 6 month PSA reduction =50%. Conclusions: Treatment with abiraterone or with enzalutamide did not lead to significant differences in the outcomes of patients with mCRPC without prior chemotherapy. Likewise, none of the analyzed variables significantly influenced treatment outcomes.
Description
Keywords
Abiraterona Enzalutamida Mcrpc